IND Application of Biosyngen’s Cell Therapy (BRG01) for Nasopharyngeal Cancer Approved by China NMPA
GUANGZHOU, China , Dec. 15, 2022 /PRNewswire/ -- On Dec. 14th, 2022, Guangzhou Biosyngen Co., Ltd. (hereinafter as "Biosyngen") made an announcement on the approval granted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) for the company's IND application for BRG01 Therapy. BRG01 Therapy is an autologous T cell therapy for relapsed/metastatic nasopharyngeal cancer...
XINGIMAGING and MITRO BIOTECH CO., LTD. to DELIVER FULL-SERVICE CRO OPERATIONS TO CHINA
NEW HAVEN, Conn., Dec. 15, 2022 /PRNewswire/ -- XINGIMAGING, LLC, and MITRO Biotech Co., Ltd. each highly recognized for drug development and imaging solutions, announce today that they will join forces to provide comprehensive contract research services in China. The company will be a leading partner to global pharmaceutical and biotechnology companies working in China and will expand its...
Stemirna receives Emergency Use Authorization from Laos for its proprietary mRNA vaccine
SHANGHAI, Dec. 14, 2022 /PRNewswire/ -- On December 8, 2022, Stemirna Therapeutics Co., Ltd. (Stemirna), a Chinese biotech startup specialized in mRNA technology-based drug development, received an Emergency Use Authorization (EUA) from the Food and Drug Department under the Ministry of Health of the Lao People's Democratic Republic for its proprietary Covid-19 mRNA vaccine which prevents infection from...
CGTN: How China strengthens vaccine cooperation to battle COVID-19
BEIJING, Dec. 15, 2022 /PRNewswire/ -- Since the outbreak of COVID-19, the world has raced against time, battling the pandemic as it wreaked havoc across the globe. Developing safe and effective vaccines is one of the most crucial steps in the fight against the virus. For the last nearly three years, China has made strides in its COVID-19 vaccine...
Innovent and LG Chem Announce Strategic Collaboration for Tigulixostat, a Novel Non-Purine Xanthine Oxidase Inhibitor for the Treatment of Gout Disease
ROCKVILLE, Md. and SUZHOU, China, Dec. 15, 2022 /PRNewswire/ -- Innovent Biologics ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune, ophthalmology and other major diseases, and LG Chem Life Sciences ("LG Chem"), a division of LG Chem, today announced that the two parties have entered into...
Alternative Bio Launches with USD 15M Series Seed Financing Led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund
SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- Alternative Bio Inc. ("ABio"), a privately held biotechnology company developing novel therapeutics targeting a previously untapped class of post-translational modifying enzymes announced today its $15 million Series Seed financing co-led by Eight Roads Ventures with F-Prime Capital and Sequoia China Seed Fund. The funds will be used to leverage an innovative discovery platform and advance...
Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone
Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically validated mRNA platform is shown to generate differentiated products across a range of indications SHANGHAI, Dec. 15, 2022 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest"), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet...
Novavax Announces Proposed $125 Million Public Offering of Common Stock
GAITHERSBURG, Md., Dec. 15, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced a proposed underwritten public offering to sell up to $125 million of its common stock. In connection with the common stock offering, Novavax expects to grant to the underwriters a 30-day option to purchase up to an additional $18.75 million of its common stock at the public offering price, less...
Introducing Kapsul ATLAS protective athletic gear
With revolutionary Dynamic Neck Stabilization Technology The biomechanically-tested neck protective shirts empower every athlete to do what they love for longer—no matter their age or skill level. WATERLOO, ON, Dec. 15, 2022 /PRNewswire/ -- Kapsul Tech Corp. today announced the Kapsul ATLAS, a lightweight and flexible shirt with a protective collar designed...
Sirnaomics Announces Positive Interim Data from Phase IIb Clinical Trial of STP705 in Adults with Cutaneous Squamous Cell Carcinoma In Situ
Dose escalation cohort study is evaluating the safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with isSCC GERMANTOWN, Md. and SUZHOU BIOBAY, China, Dec. 14, 2022 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced today the interim...
